These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 34916086

  • 1. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
    Saad F, Small EJ, Feng FY, Graff JN, Olmos D, Hadaschik BA, Oudard S, Londhe A, Bhaumik A, Lopez-Gitlitz A, Thomas S, Mundle SD, Chowdhury S, Smith MR.
    Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
    [Abstract] [Full Text] [Related]

  • 2. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
    Small EJ, Chi KN, Chowdhury S, Bevans KB, Bhaumik A, Saad F, Chung BH, Karsh LI, Oudard S, De Porre P, Brookman-May SD, McCarthy SA, Mundle SD, Uemura H, Smith MR, Agarwal N.
    Eur Urol Oncol; 2024 Aug; 7(4):844-852. PubMed ID: 38072759
    [Abstract] [Full Text] [Related]

  • 3. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
    Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Juárez Soto Á, Uemura H, Ye D, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN.
    Ann Oncol; 2023 May; 34(5):477-485. PubMed ID: 36858151
    [Abstract] [Full Text] [Related]

  • 4. Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
    Oudard S, Hadaschik B, Saad F, Cella D, Basch E, Graff JN, Uemura H, Dibaj S, Li S, Brookman-May SD, De Porre P, Bevans KB, Trudeau JJ, Small EJ, Smith MR.
    Eur Urol Focus; 2022 Jul; 8(4):958-967. PubMed ID: 34479838
    [Abstract] [Full Text] [Related]

  • 5. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
    Feng FY, Thomas S, Saad F, Gormley M, Yu MK, Ricci DS, Rooney B, Brookman-May S, McCarthy S, Olmos D, Chowdhury S, Hadaschik B, Liu Y, Davicioni E, Smith MR, Small EJ.
    JAMA Oncol; 2021 Jul 01; 7(7):1005-1014. PubMed ID: 34081076
    [Abstract] [Full Text] [Related]

  • 6. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
    Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE.
    Eur Urol; 2016 Dec 01; 70(6):963-970. PubMed ID: 27160947
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Dearden L, Capone C, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2022 Jan 01; 39(1):518-531. PubMed ID: 34797506
    [Abstract] [Full Text] [Related]

  • 9. Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study.
    Hegele A, Häußermann R, Schultheis S, Skrobek L, Vink M, Hollwegs S, Ludwig M, Huwe P, Maywurm M, Bartsch-Polle A, Weber J, Thiemer M, Varughese D.
    J Cancer Res Clin Oncol; 2024 Sep 09; 150(9):414. PubMed ID: 39249593
    [Abstract] [Full Text] [Related]

  • 10. Apalutamide and Overall Survival in Prostate Cancer.
    Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Brookman-May SD, Li S, Zhang K, Rooney B, Lopez-Gitlitz A, Small EJ.
    Eur Urol; 2021 Jan 09; 79(1):150-158. PubMed ID: 32907777
    [Abstract] [Full Text] [Related]

  • 11. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2020 Jan 09; 37(1):501-511. PubMed ID: 31813086
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial.
    Roy S, Malone S, Wing K, Chowdhury S, Kishan AU, Sun Y, Wallis CJD, Mohamad O, Jia AY, Swami U, Zaorsky NG, Morgan SC, Ong M, Agarwal N, Spratt DE, Small EJ, Saad F.
    JAMA Netw Open; 2024 Oct 01; 7(10):e2439434. PubMed ID: 39405060
    [Abstract] [Full Text] [Related]

  • 14. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
    Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, Brookman-May SD, Rooney B, Bhaumik A, McCarthy SA, Bevans KB, Mundle SD, Small EJ, Smith MR, Graff JN.
    Br J Cancer; 2024 Jan 01; 130(1):73-81. PubMed ID: 37951974
    [Abstract] [Full Text] [Related]

  • 15. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
    Matsubara N, Chi KN, Özgüroğlu M, Rodriguez-Antolin A, Feyerabend S, Fein L, Alekseev BY, Sulur G, Protheroe A, Li S, Mundle S, De Porre P, Tran N, Fizazi K.
    Eur Urol; 2020 Apr 01; 77(4):494-500. PubMed ID: 31843335
    [Abstract] [Full Text] [Related]

  • 16. Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies.
    Karsh LI, Bevans KB, Saad F, Chung BH, Oudard S, Brookman-May SD, McCarthy SA, Smith MR, Chi KN, Small EJ, Agarwal N.
    Future Oncol; 2024 Aug 20; ():1-10. PubMed ID: 39163505
    [Abstract] [Full Text] [Related]

  • 17. Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.
    Merseburger AS, Agarwal N, Bjartell A, Uemura H, Soto AJ, Bhaumik A, Böhm J, Tran N, Krochmann N, Nematian-Samani M, Mundle SD, Brookman-May SD, Lopez-Gitlitz A, McCarthy SA, Chi K, Chowdhury S.
    BJU Int; 2024 Jun 28. PubMed ID: 38940282
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Apalutamide, Erleada®].
    Sautois B, Denis C.
    Rev Med Liege; 2022 Oct 28; 77(10):609-615. PubMed ID: 36226398
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.